AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

Preoperatively assessing anemia as a modifiable risk factor may counteract increased mortality risk for patients with severe ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...